Ionis Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount
Ionis Pharmaceuticals, Inc. (IONS) reported Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount of $2.79 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-02.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense · last filed 2015-03-02
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, noncontrolling interest income (loss), amount for fiscal 2014 was $2.79M.
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, noncontrolling interest income (loss), amount for fiscal 2013 was $0.00.
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, noncontrolling interest income (loss), amount for fiscal 2012 was $0.00.
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, noncontrolling interest income (loss), amount for fiscal 2011 was -$1.45M.
| Period end | Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount 12 month |
|---|---|
| 2014-12-31 | $2.79M 10-K · filed 2015-03-02 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-02 |
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
| 2011-12-31 | -$1.45M 10-K · filed 2014-03-03 |
| 2010-12-31 | -$908.00K 10-K · filed 2013-02-28 |
| 2009-12-31 | -$3.56M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |